Compare TONX & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TONX | MDWD |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.6M | 162.2M |
| IPO Year | 2013 | 2013 |
| Metric | TONX | MDWD |
|---|---|---|
| Price | $2.98 | $12.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.67 |
| AVG Volume (30 Days) | ★ 182.4K | 79.3K |
| Earning Date | 11-11-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,000.00 | N/A |
| Revenue This Year | N/A | $39.60 |
| Revenue Next Year | N/A | $34.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 433.33 | N/A |
| 52 Week Low | $1.75 | $11.84 |
| 52 Week High | $4.44 | $19.70 |
| Indicator | TONX | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 44.30 | 39.47 |
| Support Level | $2.85 | $11.84 |
| Resistance Level | $3.58 | $14.06 |
| Average True Range (ATR) | 0.17 | 0.50 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 39.07 | 11.54 |
TON Strategy Co is a digital asset treasury and Web3 ecosystem company focused on supporting The Open Network, a public blockchain integrated with Telegram and designed for fast, scalable transactions and decentralized applications. Its core business is managing its holdings of Toncoin (TON), including staking tokens to support network validation and earn rewards, while adhering to regulatory, accounting, and risk management standards. The company also pursues Web3 initiatives to support the ecosystem's growth and adoption. It operates through MARKET. live, Go Fund Yourself, and TON segments, with MARKET.live generating maximum revenue as a multi-vendor livestream shopping platform that combines e-commerce and entertainment across social and video channels.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.